期刊
ARCHIVES OF PHARMACAL RESEARCH
卷 38, 期 12, 页码 2106-2119出版社
PHARMACEUTICAL SOC KOREA
DOI: 10.1007/s12272-015-0648-x
关键词
Alzheimer's disease; Amyloidogenesis; Anti-inflammatory; Beta-amyloid; Neuroinflammation
资金
- Yeungnam University Research Grant
Alzheimer's disease (AD) is the most common form of dementia. It is characterized by beta-amyloid (A beta) peptide fibrils, which are extracellular depositions of a specific protein, and is accompanied by extensive neuroinflammation. Various studies have demonstrated risk factors that can affect AD pathogenesis, and they include accumulation of A beta, hyperphosphorylation of tau protein, and neuroinflammation. Among these detrimental factors, neuroinflammation has been highlighted by epidemiologic studies suggesting that use of anti-inflammatory drugs could significantly reduce the incidence of AD. Evidence suggests that astrocytes, microglia, and infiltrating immune cells from periphery might contribute to or modify the process of neuroinflammation and neurodegeneration in AD brains. In addition, recent data indicate that microRNAs may affect neuroinflammatory responses in the brain. This article focuses on supportive evidence that neuroinflammation plays a critical role in AD development. In addition, we depict putative therapeutic capacity of anti-inflammatory drugs for AD prevention or treatment. We also discuss pathogenic mechanisms by which astrocytes, microglia, T cells and microRNA participate in AD and the neuroprotective mechanisms of anti-inflammatory drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据